{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:32Z","timestamp":1787026532102,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Radiation resistance significantly hinders the efficacy of radiotherapy for meningiomas, posing a primary obstacle. The clinical inadequacy of therapeutic drugs and radiosensitizers for treating meningiomas further exacerbates the challenge. Therefore, the aim of this study was to identify potential radiosensitizers for treating meningiomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A high content clonogenic survival drug screening was employed to evaluate 166 FDA-approved compounds across varied concentration ranges. Cell viability, apoptosis, and radiosensitization were assessed using CCK-8 assays, Annexin V-FITC\/PI assays and standard colony formation assays. Transcriptome sequencing, immunofluorescence and cell cycle experiments were conducted to assess transcriptional profile, DNA double-strand break damage and cell cycle distribution. Finally, the radiosensitizing effect of Maytansine was assessed\n                      <jats:italic>in vivo<\/jats:italic>\n                      through subcutaneous tumor implantation in nude mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The proportion of maytansine exhibiting SRF\u22651.5 within the detectable concentration range was 100%. CCK-8 assay indicated the IC50 values of maytansine for IOMM-Lee and CH157 were 0.26 \u00b1 0.06 nM and 0.31 \u00b1 0.01 nM, respectively. Standard clonogenic survival assays and Annexin V-FITC\/PI assays revealed maytansine had a notable radiosensitizing effect on meningioma cells. Transcriptome sequencing analysis demonstrated that maytansine can modulate cell cycle and DNA damage repair. Immunofluorescence analysis of \u03b3-H2AX and cell cycle experiments demonstrated that Maytansine enhances DNA double-strand breaks and induces G2\/M phase arrest. Moreover,\n                      <jats:italic>in vivo<\/jats:italic>\n                      studies had indicated that Maytansine augments the therapeutic efficacy of radiotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlighted the potential of maytansine as a potent inhibitor and radiosensitizer for meningiomas by inducing G2\/M phase cell cycle arrest and enhancing DNA double-strand break damage. These findings opened up a promising path in the development of radiosensitizers aimed at treating this condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1557165","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:03:23Z","timestamp":1742277803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinxiu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-oncology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro-oncology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","article-title":"Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539","volume":"129","author":"Rogers","year":"2018","journal-title":"J neurosurgery"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.11.006","article-title":"Long-term outcomes of newly diagnosed resected atypical meningiomas and the role of adjuvant radiotherapy","volume":"122","author":"Zhi","year":"2019","journal-title":"World neurosurgery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1227\/01.NEU.0000330399.55586.63","article-title":"Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation","volume":"64","author":"Aghi","year":"2009","journal-title":"Neurosurgery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-014-2156-z","article-title":"Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment","volume":"156","author":"Hammouche","year":"2014","journal-title":"Acta neurochirurgica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3171\/2010.1.JNS091114","article-title":"Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas","volume":"113","author":"Sughrue","year":"2010","journal-title":"J neurosurgery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3171\/2011.5.JNS11112","article-title":"Radiotherapy for atypical meningiomas","volume":"115","author":"Mair","year":"2011","journal-title":"J neurosurgery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1219-y","article-title":"The role of adjuvant radiotherapy in atypical meningioma","volume":"115","author":"Park","year":"2013","journal-title":"J neuro-oncology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou098","article-title":"Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma","volume":"16","author":"Aizer","year":"2014","journal-title":"Neuro-oncology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jocn.2015.09.021","article-title":"Early adjuvant radiotherapy in the treatment of atypical meningioma","volume":"28","author":"Jenkinson","year":"2016","journal-title":"J Clin neuroscience: Off J Neurosurgical Soc Australasia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.08.023","article-title":"Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control","volume":"46","author":"Dohm","year":"2017","journal-title":"J Clin neuroscience: Off J Neurosurgical Soc Australasia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.08.092","article-title":"Treatment protocol, long-term follow-up, and predictors of mortality in 302 cases of atypical meningioma","volume":"122","author":"Li","year":"2019","journal-title":"World neurosurgery"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.07.148","article-title":"Survival and prognostic predictors of anaplastic meningiomas","volume":"131","author":"Masalha","year":"2019","journal-title":"World neurosurgery"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.07.140","article-title":"Survival benefit of adjuvant radiotherapy in elderly patients with WHO grade III meningioma","volume":"131","author":"Zhou","year":"2019","journal-title":"World neurosurgery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyy610","article-title":"Malignant meningioma: an international multicentre retrospective study","volume":"85","author":"Champeaux","year":"2019","journal-title":"Neurosurgery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03711-z","article-title":"Outcomes of salvage radiation for recurrent world health organization grade II meningiomas: a retrospective cohort study","volume":"152","author":"Momin","year":"2021","journal-title":"J neuro-oncology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.1712","article-title":"High-content clonogenic survival screen to identify chemoradiation sensitizers","volume":"111","author":"Ye","year":"2021","journal-title":"Int J Radiat oncology biology physics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000199","article-title":"A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer","volume":"9","author":"Lin","year":"2014","journal-title":"J Thorac oncology: Off Publ Int Assoc Study Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0305-7372(78)80014-0","article-title":"Maytansine","volume":"5","author":"Issell","year":"1978","journal-title":"Cancer Treat Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.12.011","article-title":"alpha(v)beta(3) Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo","volume":"259","author":"Zhong","year":"2017","journal-title":"J Controlled Release"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1039\/D1CC06809A","article-title":"Targeted delivery of maytansine to liver cancer cells via galactose-modified supramolecular two-dimensional glycomaterial","volume":"58","author":"Xie","year":"2022","journal-title":"Chem Commun (Camb)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202109609","article-title":"Biomimetic nanoerythrosome-coated aptamer-DNA tetrahedron\/maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2-positive breast cancer","volume":"34","author":"Ma","year":"2022","journal-title":"Adv Mater"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0142","article-title":"In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2\u2019-deacetyl-N2\u2019-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells","volume":"64","author":"Tassone","year":"2004","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2019.1704942","article-title":"Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer","volume":"27","author":"Yu","year":"2020","journal-title":"Drug Deliv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/ja00759a054","article-title":"Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus","volume":"94","author":"Kupchan","year":"1972","journal-title":"J Am Chem Soc"},{"key":"B29","article-title":"A therapeutic trial of maytansine","volume":"1","author":"Blum","year":"1978","journal-title":"Cancer Clin Trials"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2017.10.008","article-title":"Gemtuzumab ozogamicin (GO) inclusion to induction chemotherapy eliminates leukemic initiating cells and significantly improves survival in mouse models of acute myeloid leukemia","volume":"20","author":"Zhang","year":"2018","journal-title":"Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.4081\/hr.2017.7028","article-title":"Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia","volume":"9","author":"Gottardi","year":"2017","journal-title":"Hematol Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/COC.0000000000000769","article-title":"Adjuvant trastuzumab emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive breast cancer: single-center preliminary results","volume":"43","author":"Zolcsak","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01408-7","article-title":"Trastuzumab emtansine: A review of its adjuvant use in residual invasive HER2-positive early breast cancer","volume":"80","author":"Lyseng-Williamson","year":"2020","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell Malignancies and AML: A new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"key":"B37","article-title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance","volume":"8","author":"Silva","year":"2015","journal-title":"Int J Clin Exp pathology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9210-5","article-title":"The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas","volume":"81","author":"Nathoo","year":"2007","journal-title":"J neuro-oncology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01633","article-title":"Clinical significance of somatostatin receptor (SSTR) 2 in meningioma","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now060","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro-oncology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2020.09.015","article-title":"Efficacy of (177)Lu-dotatate therapy in the treatment of recurrent meningioma","volume":"5","author":"Zahid","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac206","article-title":"Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas","volume":"25","author":"Youngblood","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ph14050427","article-title":"Antibody-drug conjugate to treat meningiomas","volume":"14","author":"Chen","year":"2021","journal-title":"Pharm (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:03:27Z","timestamp":1742277807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2025.1557165"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1557165","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"article-number":"1557165"}}